Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03248297
Other study ID # CHI UAB MISP # 54628
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 12, 2018
Est. completion date October 1, 2020

Study information

Verified date March 2022
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study, performed over a course of 3 years in 5 collaborating hospitals in Cameroon, Africa, will randomize 750 women in labor with prolonged rupture of membranes ≥ 8 hours or prolonged labor ≥ 18 hours to identical oral regimens of 1 gram of azithromycin, 1 gram of azithromycin+2 grams of amoxicillin or placebo. Women will be followed to ascertain maternal infectious outcomes and perinatal outcomes.


Description:

This 3-arm study is a large randomized clinical trial designed to evaluate the comparative effectiveness and safety of single dose oral azithromycin or combined azithromycin+amoxicillin compared to placebo for the prevention of peripartum infections and sepsis in laboring women. We have previously shown the effectiveness of azithromycin for extended spectrum antibiotic prophylaxis in addition to the standard cephalosporin alone for reduction of post-cesarean infections. In LICs, the fraction of maternal infection and sepsis from cesarean delivery is minimal. Therefore, it is necessary to evaluate strategies aimed at reducing these morbidities in women who have vaginal births. There is an increased risk of infection in women who have prolonged labor or prolonged rupture of membranes. Drawing from our findings with azithromycin-based extended antibiotic prophylaxis for cesarean delivery, we propose to adapt the intervention and evaluate a single oral dose of azithromycin (with or without oral amoxicillin) to prevent maternal peripartum infection and sepsis. This study, performed over a course of 3 years in 5 collaborating hospitals in Cameroon, Africa, will randomize 750 women in labor with prolonged rupture of membranes ≥ 8 hours or prolonged labor ≥18 hours to 1 gram of oral azithromycin, 1 gram of azithromycin+2 grams of amoxicillin, compared to usual care (placebo). Women will be followed to ascertain maternal infectious outcomes and perinatal outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 756
Est. completion date October 1, 2020
Est. primary completion date May 15, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria: - Women = 37 weeks' viable singleton or twin gestation in labor planning a vaginal delivery with 1. Prolonged membrane rupture (=8 hours) or 2. Prolonged labor (=18 hours). Exclusion Criteria: - Clinical chorioamnionitis or any other active bacterial infection (e.g. pyelonephritis, pneumonia, abscess) at time of randomization: because standard antibiotic therapy for these conditions may confound trial intervention. - Allergy to azithromycin or amoxicillin - Plan for cesarean delivery prior to enrollment - Fetal demise or major congenital anomaly: Major congenital anomalies may confound assessment of neonatal outcomes and every attempt will be made up front to exclude them from randomization. However, some unrecognized fetal anomalies may inevitably be randomized. These will not be excluded post-randomization from the primary (maternal outcome) analysis; they will be taken into consideration in the secondary analyses of neonatal outcomes.

Study Design


Intervention

Drug:
Azithromycin
Azithromycin tablet
Azithromycin and amoxicillin
azithromycin and amoxicillin
Placebo
Placebo tablet

Locations

Country Name City State
Cameroon Cameroon Baptist Convention Health Services Bamenda

Sponsors (2)

Lead Sponsor Collaborator
University of Alabama at Birmingham Merck Sharp & Dohme LLC

Country where clinical trial is conducted

Cameroon, 

References & Publications (4)

ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery. American Society of Health-System Pharmacists. Am J Health Syst Pharm. 1999 Sep 15;56(18):1839-88. Review. — View Citation

Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999 Apr;27(2):97-132; quiz 133-4; discussion 96. — View Citation

Tita ATN, Boggess K, Saade G. Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. N Engl J Med. 2017 Jan 12;376(2):182. doi: 10.1056/NEJMc1614626. — View Citation

WHO. WHO recommendations for prevention and treatment of maternal peripartum infections. Sept 2015 http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/peripartum-infections-guidelines/en/

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Who Experienced Composite Peripartum Infection or Death Maternal peripartum infection including chorioamnionitis, endometritis, wound infection/abscess, sepsis, and death Up to 6 weeks after delivery
Secondary Number of Participants Who Experienced Pyelonephritis Other Infections Up to hospital discharge
Secondary Number of Participants Who Experienced Breast Infection Other infections Up to 6 weeks after delivery
Secondary Number of Participants Who Experienced Other Infection Includes Hepatitis B, thyroid infection, vaginal infection, viral infection, leg cellulitis, unknown abdominal infection,malaria up to 6 weeks after delivery
Secondary Number of Participants Who Experienced Fever Any fever higher than 38C up to 6 weeks after delivery
Secondary Number of Participants Who Experienced Hypothermia Any hypothermia less than 36C up to 6 weeks after delivery
Secondary Number of Participants Who Needed PP Antibiotic Any postpartum antibiotic up to 6 weeks after delivery
Secondary Number of Participants Who Experienced Transfusion Blood transfusion up to 6 weeks after delivery
Secondary Number of Participants Who Experienced Stillbirth Any stillbirth delivery
Secondary Length of Stay Length of stay in days up to 6 weeks postpartum
Secondary Number of Participants Who Experienced a Clinic Visit Clinic visit after discharge up to 6 weeks after delivery
Secondary Number of Participants Who Experienced a Maternal Readmission Maternal readmission up to 6 weeks after delivery
See also
  Status Clinical Trial Phase
Terminated NCT05603624 - Effect of Sterile Versus Clean Gloves Intrapartum and Postpartum Infections at Term N/A
Completed NCT01437228 - Does Preoperative Vaginal Preparation With Povidone-iodine Before Cesarean Delivery Reduce the Risk of Endometritis? Phase 4
Completed NCT04385680 - Chlorhexidine Vaginal Preparation for Reduction of Post-cesarean Endometritis and Sepsis Phase 1/Phase 2
Terminated NCT03478163 - Antibiotics During Intrauterine Balloon Tamponade Placement Phase 4
Not yet recruiting NCT03840889 - Secondary Postpartum Hemorrhage
Completed NCT05118984 - Efficacy of Azithromycin in MSAF Cases to Improve Maternal and Neonatal Outcomes Phase 4